In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER. Sanofi (SNY) confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER; Sanofi intends to complete a share buyback program in 2025 of EUR 5B of which 72% was already repurchased.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Innate Pharma announces EUR 15M capital increase from Sanofi
- Sanofi’s Strong Financial Performance and Promising R&D Pipeline Justify Buy Rating
- Innate Pharma regains rights to Anket, announces potential Sanofi investment
- Sanofi’s Dupixent Gains FDA Approval for Chronic Spontaneous Urticaria
- Trump looking at cutting drug prices to international levels, Reuters says